Chronic kidney disease after nonrenal solid-organ transplantation

Journal of the American Society of Nephrology

Volumn 18, Issue 12, 2007, Pages 3031-3041

  Bloom, Roy D ^a   Reese, Peter P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AEBO 71; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; BELATACEPT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUINAPRIL; RAPAMYCIN; SEVELAMER; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANEMIA; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; COMORBIDITY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POLYOMA VIRUS; POPULATION; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; SHORT SURVEY; VIRUS INFECTION;

EID: 36849005395     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2007040394     Document Type: Short Survey

References (104)

1. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931-940, 2003
2. Bloom RD, Doyle AM: Kidney disease after heart and lung transplantation. Am J Transplant 6: 671-679, 2006
3. Greenberg A, Thompson ME, Griffith BJ, Hardesty RL, Kormos RL, el-Shahawy MA, Janosky JE, Puschett JB: Cyclosporine nephrotoxicity in cardiac allograft patients: A seven-year follow-up. Transplantation 50: 589-593, 1990
4. Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC, Theodore J: The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 26: 643-648, 1995
5. Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME: Predictors of renal function following lung or heart-lung transplantation. Kidney Int 61: 2228-2234, 2002
6. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D: Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 63: 664-668, 1997
7. Myers BD, Newton L: Cydosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 2[Suppl]: S45-S52, 1991
8. O'Riordan A, Wong V, McCormick PA, Hegarty JE, Watson AJ: Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 21: 2630-2636, 2006
9. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB: Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transpl 10: 301-309, 2004
10. Nair S, Verma S, Thuluvath PJ: Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 35: 1179-1185, 2002
11. Borrows R, Cockwell P: Measuring renal function in solid organ transplant recipients. Transplantation 83: 529-531, 2007
12. Broekroelofs J, Stegeman CA, Navis GJ, de Haan J, van der Bij W, de Boer WJ, de Zeeuw D, de Jong PE: Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable? J Heart Lung Transplant 19: 256-262, 2000
13. Delanaye P, Nellessen E, Grosch S, Depas G, Cavalier E, Defraigne JO, Chapelle JP, Krzesinski JM, Lancellotti P: Creatinine-based formulae for the estimation of glomerular filtration rate in heart transplant recipients. Clin Transplant 20: 596-603, 2006
14. Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, Glotz D: Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 5: 1120-1129, 2005
15. Rubel JR, Milford EL, McKay DB, Jarcho JA: Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant 23: 289-300, 2004
16. Boyle JM, Moualla S, Arrigain S, Worley S, Bakri MH, Starling RC, Heyka R, Thakar CV: Risks and outcomes of acute kidney injury requiring dialysis after cardiac transplantation. Am J Kidney Dis 48: 787-796, 2006
17. Davis CL: Impact of pretransplant renal failure: When is listing for kidney-liver indicated? Liver Transpl 11 : S35-S44, 2005
18. Canales M, Youssef P, Spong R, Ishani A, Savik K, Hertz M, Ibrahim HN: Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am J Transplant 6: 2157-2163, 2006
19. Guitard J, Ribes D, Kamar N, Cointault O, Lavayssiere L, Esposito L, Rostaing L, Muscari F, Sue B, Peron JM: Predictive factors for chronic renal failure one year after orthotopic liver transplantation. Ren Fail 28: 419-425, 2006
20. US Department of Health and Human Services: 2005 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1995-2004, Rockville, MD. Health Resources and Services Administration Healthcare Systems Bureau, Division of Transplantation
21. McGuire BM, Julian BA, Bynon JS Jr, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE: Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 144: 735-741, 2006
22. Rocha PN, Rocha AT, Palmer SM, Davis RD, Smith SR: Acute renal failure after lung transplantation: Incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant 5: 1469-1476, 2005
23. Alam A, Badovinac K, Ivis F, Trpeski L, Cantarovich M: The outcome of heart transplant recipients following the development of end-stage renal disease: Analysis of the Canadian Organ Replacement Register (CORR). Am J Transplant 7: 461-465, 2007
24. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB: Renal replacement therapy and orthotopic liver transplantation: The role of continuous veno-venous hemodialysis. Transplantation 71: 1424-1428, 2001
25. Canver CC, Heisey DM, Nichols RD: Acute renal failure requiring hemodialysis immediately after heart transplantation portends a poor outcome. J Cardiovasc Surg (Torino) 41: 203-206, 2000
26. Israni A, Brozena S, Pankewycz O, Grossman R, Bloom R: Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 39: E16, 2002
27. Randhawa P, Brennan DC: BK virus infection in transplant recipients: An overview and update. Am J Transplant 6: 2000-2005, 2006
28. Thomas LD, Vilchez RA, White ZS, Zanwar P, Milstone AP, Butel JS, Dummer S: A prospective longitudinal study of Polyomavirus shedding in lung-transplant recipients. J Infect Dis 195: 442-449, 2007
29. Randhawa P, Uhrmacher J, Pasculle W, Vats A, Shapiro R, Eghtsead B, Week K: A comparative study of BK and JC virus infections in organ transplant recipients. J Med Virol 77: 238-243, 2005
30. Munoz P, Fogeda M, Bouza E, Verde E, Palomo J, Banares R: Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis 41:1720-1725, 2005
31. Schmid H, Burg M, Kretzler M, Banas B, Grone HJ, Kliem V: BK virus associated nephropathy in native kidneys of a heart allograft recipient. Am J Transplant 5: 1562-1568, 2005
32. Limaye AP, Smith KD, Cook L, Groom DA, Hunt NC, Jerome KR, Boeckh M: Polyoma-virus nephropathy in native kidneys of nonrenal transplant recipients. Am J Transplant 5: 614-620, 2005
33. Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzzi G: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 43: 706-711, 1993
34. Ramzy D, Rao V, Tumiati LC, Xu N, Miriuka S, Delgado D, Ross HJ: Role of endothelial and nitric oxide bioavailability in transplant-related vascular injury: Comparative effects of rapamycin and cyclosporine. Circulation 114: 1214-1219, 2006
35. Fellstrom B: Cyclosporine nephrotoxicity. Transplant Proc 36: 220S-223S, 2004
36. Binet I, Wallnofer A, Weber C, Jones R, Thiel G: Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int 57: 224-231, 2000
37. Bertani T, Ferrazzi P, Schieppati A, Ruggenenti P, Gamba A, Parenzan L, Mecca G, Perico N, Imberti O, Remuzzi A, et al.: Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 40: 243-250, 1991
38. Sis B, Dadras F, Khoshjou F, Cockfield S, Mihatsch MJ, Solez K; Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. Am J Transplant 6: 1444-1450, 2006
39. Moreno JM, Ruiz MC, Ruiz N, Gomez I, Vargas F, Asensio C, Osuna A: Modulation factors of oxidative status in stable renal transplantation. Transplant Proc 37: 1428-1430, 2005
40. Ovuworie CA, Fox ER, Chow CM, Pascual M, Shih VE, Picard MH, Tolkoff-Rubin NE: Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. Transplantation 72: 1385-1388, 2001
41. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S: Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 62: 2257-2263, 2002
42. Langham RG, Egan MK, Dowling JP, Gilbert RE, Thomson NM: Transforming growth factor-betal and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 72: 1826-1829, 2001
43. Waiser J, Dell K, Bohler T, Dogu E, Gaedeke J, Budde K, Neumayer HH: Cyclosporine A up-regulates the expression of TGF-beta 1 and its receptors type I and type II in rat mesangial cells. Nephrol Dial Transplant 17: 1568-1577, 2002
44. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT: Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 55: 2407-2414, 1999
45. Gallon L, Akalin E, Lynch P, Rothberg L, Parker M, Schiano T, Abecassis M, Murphy B: ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Transplantation 81: 463-468, 2006
46. Deniz H, Ogutmen B, Cakalagaoglu F, Tuglular S, Ozener C, Akoglu E: Inhibition of the renin angiotensin system decreases fibrogenic cytokine expression in tacrolimus nephrotoxicity in rats. Transplant Proc 38: 483-486, 2006
47. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V: Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 55: 2457-2466, 1999
48. Margreiter R: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 359: 741-746, 2002
49. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 4: 583-595, 2004
50. Tamura K, Fujimura T, Tsutsumi T, Nakamura K, Ogawa T, Atumaru C, Hirano Y, Ohara K, Ohtsuka K, Shimomura K, et al.: Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 59: 1606-1613, 1995
51. van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP: Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 13: 213-220, 2002
52. Varghese Z, Fernando RL, Turakhia G, Psimenou E, Brunton C, Fernando ON, Davenport A, Burns A, Sweny P, Powis SH, Moorhead JF: Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. Transplant Proc 30: 2043-2046, 1998
53. Garlicki M, Czub P, Labus K, Ehrlich MP, Rdzanek H: Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. Ann Transplant 11: 24-27, 2006
54. Cantarovich D, Renou M, Megnigbeto A, Giral-Classe M, Hourmant M, Dantal J, Blancho G, Karam G, Soulillou JP: Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. Transplantation 79: 72-78, 2005
55. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons W, First R: Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-Year report. Am J Transplant 6: 1377-1386, 2006
56. Pratschke J, Neuhaus R, Tullius SG, Haller GW, Jonas S, Steinmueller T, Bechstein WO, Neuhaus P: Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 64: 938-940, 1997
57. Lucey MR, Abdelmalek MF, Gagliardi R, Granger D, Holt C, Kam I, Klintmalm G, Langnas A, Shetty K, Tzakis A, Woodle ES: A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status. Am J Transplant 5: 1111-1119, 2005
58. Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM: Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 77: 1457-1459, 2004
59. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G: Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 73: 732-736, 2002
60. Epstein A, Beall A, Wynn J, Mulloy L, Brophy CM: Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. Surgery 123: 456-460, 1998
61. Peura JL, Zile MR, Feldman DS, VanBakel AB, McClure C, Uber W, Haynes H, Pereira NL: Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients. J Heart Lung Transplant 24: 1969-1972, 2005
62. Silverbom M, Jeppsson A, Martensson G, Nilsson F: New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 24: 1536-1543, 2005
63. Ventura HO, Mehra MR, Stapleton DD, Smart FW: Cyclosporine-induced hypertension in cardiac transplantation. Med Clin North Am 81: 1347-1357, 1997
64. Gonwa TA: Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 7: S22-S26, 2001
65. Gleissner CA, Murat A, Schafer S, Klingenberg R, Koch A, Remppis A, Zimmermann R, Katus HA, Dengler TJ: Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation 77: 710-717, 2004
66. Webster AC, Lee VW, Chapman JR, Craig JC: Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 81: 1234-1248, 2006
67. Hunt BJ, Amin S, Halil O, Yacoub M: The prevalence, course, and characteristics of chronic anemia after heart and lung transplantation. Transplantation 53: 1251-1256, 1992
68. End A, Stift A, Wieselthaler G, Griesmacher A, Schlechta B, Koppensteiner R, Schreiner W, Geissler K, Stockenhuber F, Klepetko W: Anemia and erythropoietin levels in lung transplant recipients. Transplantation 60: 1245-1251, 1995
69. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC: Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13: 1374-1380, 2002
70. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA: New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 10: 349-355, 2004
71. Velidedeoglu E, Bloom RD, Crawford MD, Desai NM, Campos L, Abt PL, Markmann JW, Mange KC, Olthoff KM, Shaked A, Markmann JF: Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation 77: 553-556, 2004
72. Odim J, Wheat J, Laks H, Kobashigawa J, Gjertson D, Osugi A, Mukherjee K, Saleh S: Peri-operative renal function and outcome after orthotopic heart transplantation. J Heart Lung Transplant 25: 162-166, 2006
73. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49: S12-S154, 2007
74. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560-2572, 2003
75. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
76. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421-2431, 2002
77. Brozena SC, Johnson MR, Ventura H, Hobbs R, Miller L, Olivari MT, Clemson B, Bourge R, Quigg R, Mills RM Jr, Naftel D: Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail. J Am Coll Cardiol 27: 1707-1712, 1996
78. Lin J, Valeri AM, Markowitz GS, D'Agati VD, Cohen DJ, Radhakrishnan J: Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 73: 783-788, 2002
79. Artz MA, Hilbrands LB, Borm G, Assmann KJ, Wetzels JF: Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 19: 2852-2857, 2004
80. Minghelli G, Seydoux C, Goy JJ, Burnier M: Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 66: 268-271, 1998
81. Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X, Garcia-Retortillo M, Garcia-Valdecasas JC, Rodes J: Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78: 686-691, 2004
82. Soccal PM, Gasche Y, Favre H, Spiliopoulos A, Nicod LP: Improvement of drug-induced chronic renal failure in lung transplantation. Transplantation 68: 164-165, 1999
83. Boyer O, Le Bidois J, Dechaux M, Gubler MC, Niaudet P: Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 79: 1405-1410, 2005
84. Barkmann A, Nashan B, Schmidt HH, Boker KH, Emmanouilidis N, Rosenau J, Bahr MJ, Hoffmann MW, Manns MP, Klempnauer J, Schlitt HJ: Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 69: 1886-1890, 2000
85. Orlando G, Baiocchi L, Cardillo A, Iaria G, De Liguori N, De Luca L, Ielpo B, Tariciotti L, Angelico M, Tisone G: Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 13: 46-54, 2007
86. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC, Kahan BD: Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 12: 1059-1071, 2001
87. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 356: 194-202, 2000
88. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-Year results of the Rapamune Maintenance Regimen Study. Transplantation 76: 364-370, 2003
89. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM: Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 5: 2318-2323, 2005
90. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F: Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 21: 3252-3257, 2006
91. Snell GI, Levvey BJ, Chin W, Kotsimbos T, Whitford H, Waters KN, Richardson M, Williams TJ: Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 21: 540-546, 2002
92. Zakliczynski M, Nozynski J, Zakliczynska H, Rozentryt P, Zembala M: Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc 35: 2331-2332, 2003
93. Trosch F, Rothenburger M, Schneider M, Welp H, Etz C, Wilhelm MJ, Scheid HH, Schmid C: First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 52: 163-168, 2004
94. Groetzner J, Wittwer T, Kaczmarek I, Ueberfuhr P, Strauch J, Nagib R, Meiser B, Franke U, Reichart B, Wahlers T: Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 81: 355-360, 2006
95. Nair S, Eason J, Loss G: Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 9: 126-129, 2003
96. Jayasena SD, Riaz A, Lewis CM, Neild GH, Thompson FD, Woolfson RG: Outcome in patients with end-stage renal disease following heart or heart-lung transplantation receiving peritoneal dialysis. Nephrol Dial Transplant 16: 1681-1685, 2001
97. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N: Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: Where will MELD lead us? Am J Transplant 6: 2651-2659, 2006
98. Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Reddy KR: Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 11: 1048-1055, 2005
99. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Deng MC, Keck BM, Hertz MI; Registry of the International Society for Heart and Lung Transplantation: Twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 24: 945-955, 2005
100. Fong TL, Bunnapradist S, Jordan SC, Selby RR, Cho YW: Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation. Transplantation 76: 348-353, 2003
101. Davis CL, Gonwa TA, Wilkinson AH: Identification of patients best suited for combined liver-kidney transplantation: Part II. Liver Transpl 8: 193-211, 2002
102. Pieper AK, Buhle F, Bauer S, Mai I, Budde K, Haffner D, Neumayer HH, Querfeld U: The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant 19: 2630-2633, 2004
103. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD: Combined therapy with atorvastatin and calcineurin inhibitors: No interactions with tacrolimus. Am J Transplant 5: 2236-2243, 2005
104. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353: 770-781, 2005